Consilium Wealth Advisory LLC Purchases 3,175 Shares of Johnson & Johnson (NYSE:JNJ)

Consilium Wealth Advisory LLC raised its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 62.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 8,294 shares of the company's stock after buying an additional 3,175 shares during the quarter. Consilium Wealth Advisory LLC's holdings in Johnson & Johnson were worth $1,375,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the company. Tallon Kerry Patrick bought a new position in Johnson & Johnson in the 4th quarter worth about $290,000. Capital & Planning LLC boosted its position in shares of Johnson & Johnson by 13.6% in the fourth quarter. Capital & Planning LLC now owns 1,528 shares of the company's stock valued at $221,000 after acquiring an additional 183 shares during the period. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after acquiring an additional 6,332 shares during the period. Union Bancaire Privee UBP SA purchased a new stake in Johnson & Johnson in the 4th quarter worth approximately $85,886,000. Finally, V Square Quantitative Management LLC boosted its holdings in Johnson & Johnson by 3.9% in the 4th quarter. V Square Quantitative Management LLC now owns 47,319 shares of the company's stock valued at $6,843,000 after purchasing an additional 1,778 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 1.1%

Shares of Johnson & Johnson stock traded down $1.61 during trading on Wednesday, reaching $150.77. The company's stock had a trading volume of 8,323,506 shares, compared to its average volume of 7,959,915. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $169.99. The firm's 50-day moving average is $154.03 and its two-hundred day moving average is $153.69. The company has a market cap of $362.76 billion, a price-to-earnings ratio of 16.77, a PEG ratio of 2.35 and a beta of 0.42.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 3.45%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson's dividend payout ratio (DPR) is presently 57.84%.

Analysts Set New Price Targets

Several research analysts have recently weighed in on JNJ shares. Barclays decreased their price target on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating on the stock in a report on Thursday, April 17th. Benchmark raised Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Bank of America cut their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their target price for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $170.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.